Patents by Inventor Steven G. Reed

Steven G. Reed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210069323
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: April 22, 2020
    Publication date: March 11, 2021
    Inventors: Steven G. Reed, Darrick Carter
  • Publication number: 20210069324
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glycopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: April 22, 2020
    Publication date: March 11, 2021
    Inventors: Steven G. Reed, Darrick Carter
  • Patent number: 10940198
    Abstract: The present invention relates to a herpes zoster vaccine composition, which comprises glycoprotein E of Varicella zoster virus, a glucopyranosyl lipid adjuvant, and a metabolic oil, and selectively increases a cell-mediated immune reaction without having disadvantages of attenuated live vaccines, thereby exhibit high safety and a high preventive effect against herpes zoster.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 9, 2021
    Assignees: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Hyo Jung Nam, Eun Mi Kim, Duck Hyang Shin, Steven G. Reed, Kang Il Yoo, Sung Jun Hong
  • Publication number: 20200376116
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 3, 2020
    Inventors: Steven G. Reed, Darrick Carter
  • Publication number: 20200338180
    Abstract: Compositions and methods for preventing, treating and detecting leprosy are disclosed. The compositions generally comprise polypeptides comprising one or more Mycobacterium leprae antigens as well as polynucleotides encoding such polypeptides.
    Type: Application
    Filed: September 15, 2017
    Publication date: October 29, 2020
    Applicant: Infectious Disease Research Institute
    Inventors: Steven G. REED, Malcolm S. Duthie
  • Patent number: 10792359
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glycopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: October 6, 2020
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Patent number: 10765736
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: September 8, 2020
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Patent number: 10632191
    Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1. L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: April 28, 2020
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Publication number: 20200038498
    Abstract: The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active M. tuberculosis infection or an active infection resulting from reactivation of a latent infection in a mammal and to methods of improving the efficacy of chemotherapy regimens against active M. tuberculosis infection.
    Type: Application
    Filed: September 10, 2018
    Publication date: February 6, 2020
    Applicant: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Rhea N. Coler
  • Publication number: 20190328868
    Abstract: The present invention relates to a herpes zoster vaccine composition, which comprises glycoprotein E of Varicella zoster virus, a glucopyranosyl lipid adjuvant, and a metabolic oil, and selectively increases a cell-mediated immune reaction without having disadvantages of attenuated live vaccines, thereby exhibit high safety and a high preventive effect against herpes zoster.
    Type: Application
    Filed: December 20, 2017
    Publication date: October 31, 2019
    Applicants: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Hyo Jung NAM, Eun Mi KIM, Duck Hyang SHIN, Steven G. REED, Kang Il YOO, Sung Jun HONG
  • Publication number: 20180236063
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glycopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: January 19, 2018
    Publication date: August 23, 2018
    Inventors: Steven G. Reed, Darrick Carter
  • Publication number: 20180221470
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: November 28, 2017
    Publication date: August 9, 2018
    Applicant: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Publication number: 20180169226
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: January 11, 2018
    Publication date: June 21, 2018
    Inventors: Steven G. Reed, Darrick Carter
  • Publication number: 20180170975
    Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.
    Type: Application
    Filed: November 16, 2017
    Publication date: June 21, 2018
    Applicant: Infectious Disease Research Institute
    Inventors: Steven G. REED, Rhea N. COLER, Gregory C. IRETON, Sylvie BERTHOLET
  • Patent number: 9987355
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: June 5, 2018
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Patent number: 9950063
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: April 24, 2018
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Patent number: 9907845
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: March 6, 2018
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Patent number: 9909114
    Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise polypeptides comprising Leishmania antigens as well as polynucleotides encoding such polypeptides.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: March 6, 2018
    Assignee: INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Malcolm Duthie, Jeff Guderian, Steven G. Reed
  • Publication number: 20180028649
    Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1. L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1,Y2, Y3, Y4, R1, R2, R3 , R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.
    Type: Application
    Filed: October 10, 2017
    Publication date: February 1, 2018
    Applicant: Infectious Disease Research Institute
    Inventors: Steven G. REED, Darrick CARTER
  • Patent number: 9822152
    Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: November 21, 2017
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Rhea N. Coler, Gregory C. Ireton